Using advanced SPECT-CT scans to improve diagnosis in various diseases
Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies
This study is testing if new SPECT-CT scans can help doctors better diagnose diseases affecting the thyroid, heart, bones, brain, and kidneys without needing extra injections or radiation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Lille Catholic University Academic / other |
| Locations | 2 sites (Lomme, Hauts De France and 1 other locations) |
| Trial ID | NCT03414021 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of new gamma-cameras with semiconductor technology in nuclear medicine. It focuses on the use of SPECT-CT scans to quantify radioactivity in various organs without additional tracer injections or radiation exposure. The study aims to enhance the interpretation of scintigraphies for conditions affecting the thyroid, heart, bones, brain, and kidneys. By utilizing the SUVspect indicator, the research seeks to provide more accurate assessments of tracer distribution in clinical settings.
Who should consider this trial
Good fit: Ideal candidates include informed adult patients referred for nuclear medicine exploration.
Not a fit: Patients who refuse to participate or are under guardianship will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better management of thyroid, heart, bone, brain, and kidney diseases.
How similar studies have performed: While this approach utilizes novel technology, similar studies have shown promise in enhancing diagnostic accuracy in nuclear medicine.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: - informed adult patients referred to our department of nuclear medicine for a nuclear medicine exploration Exclusion Criteria: * Refusal to participate * Patient under guardianship
Where this trial is running
Lomme, Hauts De France and 1 other locations
- Humanitep — Lomme, Hauts De France, France (Recruiting)
- Hopital Privé Le Bois — Lille, Hauts-de-France, France (Not_yet_recruiting)
Study contacts
- Principal investigator: Tanguy Blaire, MD — Gie Humanitep, Ghicl
- Study coordinator: Marie Paule Lebitasy, MD
- Email: Lebitasy.Marie-Paule@ghicl.net
- Phone: 03 20 22 57 41
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.